PreprintPDF Available
Preprints and early-stage research may not have been peer reviewed yet.


The effects of propolis, a well-known functional food, on irritable bowel syndrome (IBS), a chronic gastrointestinal disorder, in humans have yet to be investigated. This study evaluated propolis effects in IBS subjects. In this clinical study, 56 patients with IBS diagnosed by Rome IV criteria were assigned for 6 weeks randomly to the study groups. At the baseline and endpoint phase, patients’ gastrointestinal symptoms, quality of life (QOL), anxiety state, dietary intakes, and anthropometric indices were assessed. Independent t-test, paired t-test, Mann-Whitney U test, Wilcoxon, Fisher's exact test, repeated measures analysis of variance and logistic regression test were used for analyzing the data. To adjust the effect of confounders, covariance analysis was used. The results of this study showed that after modulating the effect of potential confounders, propolis supplementation increased the chance of improving IBS severity by 6.22 (with a confidence interval of: 1.33 - 1.14 and P = 0.035). A significant abdominal pain improvement, anxiety state, and bowel habits dissatisfaction reduction was observed within- and between-group differences in propolis group compared to the placebo group (P = 0.040, P = 0.035, P = 0.029, retrospectively). The overall score of quality of life and its domains in the propolis group was statistically significant, but in comparison between the two groups, this difference was not significant. Also, regards to the food intakes and anthropometric indices, there were no significant differences between and within the two study groups. This study illustrated that propolis supplementation could be used as adjunctive therapy in IBS disease to reduce abdominal pain and anxiety state.
Page 1/15
Effects of Propolis Supplementation on The Severity of Disease In
Irritable Bowel Syndrome Subjects: A Randomized, Double-Blind
Clinical Trial
Mahsa Miryan
Tabriz University of Medical Sciences
Pejman Alavinejad
Ahvaz Jundishapur University of Medical Sciences
Mohammadreza Abbaspour
Mashhad University of Medical Sciences
Davood Soleimani
Kermanshah University of Medical Sciences
Alireza Ostadrahimi ( )
Tabriz University of Medical Sciences
Research Article
Keywords: Propolis, Irritable bowel syndrome, IBS-QOL, IBS-SSS, Dietary intake, Anxiety state
License: This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Page 2/15
The effects of propolis, a well-known functional food, on irritable bowel syndrome (IBS), a chronic gastrointestinal disorder, in
humans have yet to be investigated. This study evaluated propolis effects in IBS subjects.In this clinical study, 56 patients with IBS
diagnosed by Rome IV criteria were assigned for 6 weeks randomly to the study groups. At the baseline and endpoint phase, patients’
gastrointestinal symptoms, quality of life (QOL), anxiety state, dietary intakes, and anthropometric indices were assessed.
Independent t-test, paired t-test, Mann-Whitney U test, Wilcoxon, Fisher's exact test, repeated measures analysis of variance and
logistic regression test were used for analyzing the data. To adjust the effect of confounders, covariance analysis was used. The
results of this study showed that after modulating the effect of potential confounders, propolis supplementation increased the
chance of improving IBS severity by 6.22 (with a condence interval of: 1.33 - 1.14 and P = 0.035). A signicant abdominal pain
improvement, anxiety state, and bowel habits dissatisfaction reduction was observed within- and between-group differences in
propolis group compared to the placebo group (P = 0.040, P = 0.035, P = 0.029, retrospectively). The overall score of quality of life
and its domains in the propolis group was statistically signicant, but in comparison between the two groups, this difference was not
signicant. Also, regards to the food intakes and anthropometric indices, there were no signicant differences between and within the
two study groups. This study illustrated that propolis supplementation could be used as adjunctive therapy in IBS disease to reduce
abdominal pain and anxiety state.
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disease that is manifested by recurrent abdominal pain
and altered bowel addiction (1). No specic markers or laboratory parameters are available yet to diagnose the disease. Recently in
clinical practice, the Rome IV criteria have been proposed as the latest diagnostic tool for IBS, based on the GI symptoms (2). IBS is
estimated to affect women approximately three times more than men, with an overall prevalence of 10% (3, 4).
The pathophysiology of IBS is not well known, but several factors have been attributed to an individual’s susceptibility to IBS
including the alterations in gut microbiota, brain-gut interaction, motility or/and permeability, and intestinal immune system function;
GI microscopic inammation; psychological stress; chronic infections; specic nutrients and foods; and genetic factors (5). Recent
investigations also reveal the role of inammatory and oxidative stress factors in increasing nervous system sensitivity and
perception of abdominal pain in IBS subjects (3).
Various strategies are recommended to improve or even treat IBS symptoms but, unfortunately, often with little success so far (6).
The initial strategy would be to base the prohibition of consuming gas-producing foods by following a diet low in FODMAPs. But if
this is not helpful, the consumption of these special foods should not be avoided for a long time (7). Emerging evidence has shown
an important role of the modulating GI immune system and gut microbiota using prebiotic and/or probiotic supplements in
ameliorating the symptoms of IBS, which has been benecial for many patients (8). Dietary polyphenols and their secondary
metabolites also have a crucial role in maintaining the balance of the GI microbiome by altering bacterial metabolites that can raise
mucin gene expression that resulted in an increase in the thickness of the GI mucosal layer and also reduction in GI inammation (9).
Propolis, a popular traditional medicine, is a resinous hive product collected by honeybees from varied petals and plant buds sources
(10). With the advent of new methods such as high-performance liquid chromatography (HPLC), more than 300 types of
phytochemicals have been identied in this hive product, mainly from the family of polyphenols. They are secondary plant
metabolites with well-known antioxidant properties (11). Recent studies have been shown that propolis, due to the unique diversity of
its components (especially polyphenols), not only has antioxidant effects but also can modulate the inammatory pathways,
immune system function, gut microbiota, and GI permeability (12-15).
Considering the wide range of probable causes and symptoms in IBS patients which propolis may modify; we aimed to evaluate the
ecacy of propolis supplementation on the severity of gastrointestinal symptoms, dietary intakes, anxiety state, and quality of life in
patients with IBS.
Materials And Methods
Study design and subjects
Page 3/15
This randomized, double-blind, parallel-design, placebo-controlled clinical trial was conducted on subjects who their IBS has been
determined by a gastroenterologist according to Rome IV criteria. Patients were recruited from the Soroush Special Clinic of Ahvaz,
Iran, between September 2019 and January 2020. Based on the Rome IV criteria, patients who had recurrent abdominal pain or
discomfort (at least 1 day/week in the last 3 months) were identied as an IBS patient if he/she had at least two of the following
criteria: 
I. Improvement with defecation
II. Onset related to a change in stool frequency
III. Onset related to exchange in stool form (appearance)
Enrolled participants
The inclusion criteria in this trial included patients aged 18-65 years who had a constipation subtype of IBS (IBS-C) or a mixed
subtype of IBS (IBS-M) based on the Bristol stool form scale (BSFS); have no allergy to bee products; and ll out a written consent
form. The exclusion criteria of the study were pregnancy or breastfeeding; patients with malignancy or other chronic GI diseases;
regular use of drugs that modify GI movements (such as Metoclopramide, Cisapride, Narcotics, Diphenoxylate, and etc.); regular use
of laxatives and/or antibiotics; the history of major surgery in the digestive system (such as Billroth's operation, having an ostomy
and any resection of any part of the digestive tract); being on diet; regular use of prebiotic and/or probiotic compounds; and use of
psychotherapy drugs.
Excluded participants
Patients with taking less than 80% of their supplements, unwilling to continue collaboration in the study, experiencing severe physical
and mental trauma, or changing their diet plan or physical activity during the study were withdrawn from follow-up.
The trial protocol, available at Iranian Registry of Clinical Trials (, registration date: 26/12/2019,
Registration number: IRCT20190708044154N1), was approved by the Ethics Committee of Tabriz University of Medical Sciences.
This trial was performed in accordance with the Declaration of Helsinki. All patients were provided verbally with information on the
objectives, benets, and possible health risks of the trial at the time of enrollment and then provided written informed consent.
Randomization and intervention
Eligible patients were randomly allocated in a 1:1 ratio to receive propolis or placebo tablets. In this study, a random-number table
was used to generate randomization sequences with a block size of 4 and stratication according to IBS subtypes and sex. For
proper blinding, the propolis and placebo were prepared in precisely the same color, size, odor, and packaging. Also, numbered drug
containers were used to conceal random allocation. No one was aware of treatment assignments, except the pharmacist.
The supplements were prepared by Mashhad School of Pharmacy, Mashhad University of Medical Sciences, Iran; under the
supervision of a clinical pharmacist. Propolis tablets consist of 450 mg of propolis extract (containing 90 mg of the polyphenols and
67 mg avonoids), whereas the placebo tablets contain microcrystalline cellulose (a powder that had no taste, calories, smell, or
nutrients) and various edible colors (16). The tablets were similar in color, shape, and packaging; and were administrated before
lunch and dinner for six weeks. The optimal dosage of propolis (900mg/day) was extracted from animal studies which its method is
completely described in the published protocol article of this study (17). Due to the same mechanism of propolis and pre-and
probiotics for intestinal microora, a period of six weeks is adequate to boost intestinal microora and/or GI symptoms in patients
based on former studies (18, 19). One of the researchers was responsible for follow-up patients by phone calls, weekly. She was
asked each patient to report any adverse effect they may be experienced during the study, and ll out the supplement checklist on
which patients recorded supplements consumed. In each visit, compliance was assessed by the supplement checklists and by
counting the return of uneaten supplements.
Primary Outcome
Page 4/15
The main outcome of the trial was the percentage of patients with an improvement of at least one stage of IBS disease from
baseline to the sixth week of intervention. To assess IBS severity, the IBS symptom severity scale (IBS-SSS) was used. It was lled
out by patients pre- and post-intervention. The IBSSS questionnaire included ve clinically applicable items over a 10-day period
include: Ι) the abdominal pain intensity, ΙΙ) the frequency of abdominal pain, ΙΙΙ) the abdominal distension intensity, IV) dissatisfaction
with bowel movements, and V) potential impact of IBS on the patient’s daily life. The mean score of each scale is a maximum of 100
and the questionnaire total score reaches a maximum of 500, eventually. Scores of <75, 75-175, 175-300, and 300 displayed mild,
moderate, and severe stages of the IBS disease, respectively (20).
Secondary outcomes
The secondary outcomes of the trial were change in IBS-quality of life (IBS-QoL), anxiety state, body mass index (BMI), and waist
circumference (WC) to the sixth week of intervention. Patients’ quality of life (QoL) was assessed using the 34-item IBS-QoL
questionnaire which consists of 8 subscales including (a) food avoidance, (b) dysphoria, (c) body image, (d) interference with
activity, (e) health worry, (f) sexual, social reaction, and (g) relationships.(21) Participant responses to all the 34 items were summed
and then transformed to a 0-to-100 scale. The Beck anxiety inventory(BAI) was used to assess patients’ anxiety status. BAI is a 21-
item scale validated as an anxiety screening questionnaire based on Fydrich et al (22). Each item expresses one of the symptoms of
anxiety commonly experienced by patients who are clinically anxious or in anxious conditions. The questionnaire scores ranged from
0 to 63. The anxiety state wasclassiedas minimal (scores range from 0 to 7), mild (scores range from 8 to 15), moderate (scores
range from 16 to 25), and severe (scores range from 30 to 63) (23). Due to the anxiety isapotential confounder for the study it was
assessed before and after the intervention and its effect was adjusted at the end of the trial by the statistical analysis. Weight was
measured close to 0.1 kg by a calibrated scale (Seca, Hamburg, Germany) with light clothes and no shoes. Height was measured
close to 0.1 cm by an audiometer (Seca, Hamburg, Germany). Then, BMI was calculated as weight (kg)/height2 (m). WC was
measured as the smallest circumference between the costal and iliac crests using a non-stretchable measuring tape to the nearest
0.1 cm.
Confounding factors assessment:
Dietary intake was appraised by a three-day food record (two nonconsecutive weekdays, and one weekend) before and after the
intervention. Dietary intakes were assessed by the Nutritionist IV software. A validated international physical activity questionnaire-
short form (IPAQ-SF) was used for evaluating the physical activity of the patients at baseline and the endpoint. Responses were
converted to Metabolic Equivalent Task minutes per week (MET-min/ week). It consisted of 7 questions that will collect all types of
physical activity as part of daily life (24).
Statistical analysis
Statistical analysis was conducted using IBM SPSS Statistics software, version 16 (SPSS Inc., and Chicago, IL, USA). The sample
size was 28 patients in each group by assuming a between-group difference of 25% points in the main outcome (19) on the basis of
a two-sided signicance level of 5%, a power of 80%, and a withdrawal rate of 30% with the use of A'Hern'ssingle-stage phase II
methodology (25).
According to the patterns of missing data, a suitable multiple imputation approach followed for completing missing data. The
authors checked the data entry double times.
Data were presented as mean (SD) for numerical data, frequency (percentage) for categorical variables, and median (25th, 75th) for
values with skewed distribution. For evaluating the differences between the 2 groups at baseline, independent samples t-test or
Mann-Whitney U test were used for values with normal and non-normal distribution, respectively. Paired samples t-test and Wilcoxon
signed-rank test were used for assessing within-group changes, as appropriate. To judge between-and within-group differences of
qualitative variables, Fisher's exact test and Sign test were applied, respectively. For adjusting the confounding factors the analysis of
covariance (ANCOVA) test was used. In this study two separate models were used to achieve the goal. Model 1 included baseline
values, and model 2 included the model 1, and changes in physical activity, and energy intake. P values under 0.05 were observed as
statistically signicant. The binary logistic regression was used to calculate the odds of achieving the main outcome with propolis
supplementation in both crude and adjusted models. Further details of the study method are presented in the protocol article of this
study (17).
Page 5/15
3.1. General characteristics of the trial
Between September 2019 and January 2020, a total of 168 patients were enrolled in the trial and were screened, of whom 56 patients
met eligibility criteria and underwent randomization (28 patients to the propolis group and 28 patients to the placebo group). A total
of51 patients (26 patients in the propolis group and 25 patients in the placebo group) completed this trial while 5 patients (3 patients
in the placebo group and 2 patients in the propolis group) discontinued the study for a reason unrelated to the trial treatment and 1
patient in the propolis group discontinued the study because of a drug-related adverse event (abdominal distention). The trial
owchart is shown in Figure 1. There was no signicant differences in terms of compliance rates between the propolis and placebo
groups at the end of the trial (93% for propolis vs. 90% for placebo; P: 0.73).
3.2. Demographic characteristics
The baseline demographic characteristics of the participants in both groups are shown in Table 1. Prior to the intervention, there
were no statistically signicant differences between the two groups in terms of gender, marital status, education levels, occupational
status, physical activity levels (metabolic equivalents), IBS subtypes, duration of IBS symptoms, and anxiety state.
Dietary intakes,anthropometric indices, and physical activity
As observed in Table 2, caffeine and lactose intake had a signicant change throughout the study in both groups, whereas other
nutrients did not signicantly change. However, these changes were related to the effect of time and were not the effect of the
intervention. The intakes of energy, macronutrients, lactose, and caffeine had no signicant changes from baseline to the end of the
trial in both groups (P >0.05). None of the participants in the present study reported alcohol consumption at the beginning and during
the study. Also, there were no signicant changes in terms of weight, BMI, WC, and physical activity (METs) in the both group as
observed in Table 3.
3.3. Severity of IBS
As shown in Table 5, overall scores of IBS symptoms severity and all its components scores signicantly reduced in the propolis
group at the end of the trial (P <0.05). In the placebo group, the scores of severity of abdominal distention decreased signicantly
while other components did not change at the end of the trial (P <0.05). There were signicant between-group differences in the
severity of abdominal pain and dissatisfaction with bowel habits after adjusting the potential confounders based on model 2.
The changes in the grade of IBS are illustrated in Figure 2. At the end of the trial, the grade of IBS decreased in 21 patients (80.7%)
and had no change in 5 (19.3%) who received propolis supplements. The improvement in the grade of IBS was statistically
signicant in the propolis group (P=0.001). In the placebo group, the grade of IBS decreased in 13 (52%) patients; had no changes in
11 (44%) patients, and increased in 1 (4%) patient. The improvement in the grade of IBS was not signicant in the placebo group
(P=0.501). Mann-Whitney U test showed that the proportion of patients experienced reduction in the IBS severity by at least one grade
was signicantly higher in the propolis group than the placebo group (80.7% vs. 52% P=0.015). In addition, the adjusted odds of
improvement of IBS was 6.22 (95% CI: 1.14 to 33.9; P=0.035) with propolis treatment as compared with placebo.
3.4. Quality of life
As shown in Table 4, there were no signicant between-group changes for the total QOL-IBS and its components scores after
adjusting the potential confounders based on model 1 throughout the study, except for body image. In model 2 after adjusting the
potential confounders no signicant between-group changes were observed. The signicant within-group reduction in the QOL-IBS
and its components scores were observed in the propolis group, compared to the placebo group post-intervention (P<0.05).
3.5. Anxiety
Propolis supplementation decreased the frequency of severe anxiety in IBS patients from 23.07% to 7.69%. Additionally, it raised the
frequency of minimum anxiety from 23.07% to 34. 61%, and mild anxiety from 30.76% to 46.15% in the propolis group. Also, another
nding of this study was that there was a signicant reduction in patients’ anxiety in the propolis group versus the placebo group
Page 6/15
throughout the study (16.88 to 11.19 versus 17.68 to 16.44; P=0.040). It was also found that the anxiety score of patients’ within-
group signicantly decreased in the propolis group contrary to the placebo group (P=0.002, P=0.462, retrospectively).
The current trial revealed that supplementation with 900 mg/day of propolis for 6 weeks signicantly improved anxiety state, some
clinical symptoms of IBS in patients with IBS (abdominal pain, dissatisfaction with bowel habits). However, it had no signicant
effects on dietary intakes, anthropometric indices, quality of life, and physical activity levels. The current trial is the rst study
evaluating the eects of propolis administration in patients with IBS.
Our results showed that propolis had no signicant effect on energy intakes and energy-adjusted dietary intakes. In line with our
results, Soleimani et al. reported that the administration of 900 mg/day of propolis for 4 months in patients with non-alcoholic fatty
liver disease (NAFLD) had no signicant effect on energy and dietary intakes (16). In the study of Samadi et al., the administration of
900 mg/day propolis for 3 months did not affect the dietary intakes in the propolis group in type 2 diabetic patients (26). In another
study, consumption of 900 mg/day propolis for 18 months did not affect energy and nutrients intakes in patients with type 2
diabetes mellitus (T2DM).(27) Furthermore, another study showed the consumption of a high dose of propolis (1500 mg/day)
through 8 weeks did not affect energy and nutrients intakes in patients with T2DM (28).
Our results also showed that propolis had no signicant effect on weight, BMI, and WC after adjusting the potential confounders
such as changes in energy intakes and physical activity levels. In line with our results, the study of Soleimani et al. showed no
signicant effect of propolis administration on weight, BMI, body fat mass, and fat free mass in patients with NAFLD (16). Likewise,
Mujica et al. reported that daily consumption of 30 drops of 3% propolis extract for 3 months did not affect weight, BMI, and WC (29).
Another research showed that a daily supplement of 1500 mg of propolis for 8 months did not affect body weight and BMI (30).
Conversely, Samadi et al. reported that propolis administration (900 mg/day for 3 months) in T2DM reduced weight and BMI, while it
did not affect WC (26). This inconsistency can be effect of confounders such as changes in dietary intakes and physical activity
levels throughout the study of Samadi et al (26).
Our results also showed that propolis had no signicant effect on IBS quality of life in patients with IBS after adjusting the potential
confounders. Contrary to our ndings, Pessolato et al. reported receive 5% propolis ointment administered daily for mices with grade
2 burns on the burn sites for 21 days improved their QOL (31). Also, the study of Samet et al. showed that 500 mg/day of propolis for
6 months can improve the QOL of patients with recurrent aphthous stomatitis in the oral cavity (32).
Our results showed that propolis administration improved anxiety state in patients with IBS after adjusting the potential confounders.
The anxiolytic effects observed in propolis might be related to its terpenoids compounds, which can reduce adrenocorticotropic
hormone (ACTH) levels and subsequently reduce cortisol levels and increase the activity of the body's own antioxidant defense
system, which ultimately strengthens the antioxidant system in Brain tissue is through the hypothalamic-pituitary-adrenal axis (33).
Our results showed that propolis administration improved the IBS (score and grade) in patients with IBS after adjusting the potential
confounders. Recent systematic review of pre-clinical studies concluded that propolis intake might have benecial effects on many
aspects of clinical, macroscopic, and histological features of colitis (34). Nonetheless, limited studies examined the eects of
propolis on the severity of inammation-based diseases in humans. A human study showed propolis decreased the severity of pain
related to oral mucositis (35). Propolis by its anti-inammatory effects could reduce the inammation related to IBS disease, and
based on this study ndings it can reduce the severity of abnormal pain and dissatisfaction with bowel habits. Non-specic propolis
extract is involved in the immune response by activating macrophages, which does this by releasing hydrogen peroxide and
inhibiting the production of nitric oxide (dose-dependent effect), which can be affected by its effect on Inhibition of inducible nitric
oxide synthase (iNOS) gene expression and iNOS catalytic activity is justied (36, 37). Laboratory studies have shown the inhibitory
effect of propolis on free radicals (38, 39). Some of the specic effects shown by the aqueous form of propolis include an inhibitory
effect on platelet aggregation, an inhibitory effect on the synthesis of prostaglandins in vitro, and inhibition of 5-lipoxygenase (5-
LOX) (40-42). Studies have also shown that alcoholic propolis extract inhibits transcription of the iNOS gene through its effect on
Nuclear factor kappa B (NF-κB) sites in the NF-κB promoter, which is dose-dependent (43). Also, alcoholic extract of propolis can
interfere with inammatory response mechanisms, which has a very important effect on controlling cellular epithelial function (44).
Page 7/15
Propolis could also reduce the inammatory cytokines (45). Propolis compounds such as caffeine phenyl ester inhibit NF-κB activity
(Figure 3) (46).
The current trial had some strength. One of the most important strengths of this study was that it conducted on the IBS patients
diagnosed by Rome IV criteria which is the newest tool for IBS diagnosis; also using stratied block randomization with a block size
of 4 (based on IBS subtypes and sex) led to the distribution of features between the study groups and the other strengths of this
study were the high compliance rateofpatientsto the treatment in each group.However, this trial had a few limitations including
self-reporting of physical activity and dietary intakes.
The present trail, for the rst time, revealed that supplementation with 900 mg/day propolis for 6 weeks could signicantly improve
abdominal pain, decrease dissatisfaction with bowel habits as well as the reduction in the anxiety state. Although, propolis
supplementation had no effect on IBS-QOL, dietary intakes, and anthropometric indices. This trial suggested that propolis could be
used as adjunctive therapy in IBS disease to reduce abdominal pain and the anxiety of IBS patients. Further RCT studies on the effect
of propolis supplementation on gut microbiome of IBS patients are suggested to achieve valid data in the management of IBS.
ANCOVA: Analysis of covariance; BAI: Beck anxiety inventory; BMI: Body mass index; BSFS: Bristol stool form scale; GI:
Gastrointestinal; HPLC: High-performance liquid chromatography; IPAQ-SF: International physical activity questionnaire-short form;
IBS: Irritable bowel syndrome; IBS-C: Constipation subtype of IBS; IBS-M: Mixed subtype of IBS; IBS-QOL: Irritable bowel syndrome
quality of life; IBS-SSS: Irritable bowel syndrome symptom severity scale; iNOS; Inducible nitric oxide synthase; MCC: Microcrystalline
cellulose; METs: Metabolic equivalents; NF-kB: Nuclear factorkappa-light-chain-enhancer of activated B cells; OM: Oral mucositis;
QOL: Quality of life; WC: Waist circumference.
MM, AO, PA, DS, and MA designed research and contributed to the conception of the project, development of the overall research
plan, and study oversight. MM drafted the manuscript and analyzed and interpreted the data. MM and DS were the statistic
counselors and PA diagnosed the patients with Rome IV criteria. MM was involved in the sampling and data collection. All authors
have given nal approval of the version to be published.
Declaration of competing for interest
All authors declare that there is no conict of interest.
We sincerely thank the patients who participated in the present study.
The study was nancially supported by the Nutrition Research Center of Tabriz University of Medical Sciences. The funder is not
involved in the study design, collection, management, analysis, and interpretation, writing of the manuscript and the decision to
submit the report for publication, including whether they will have ultimate authority over any of these activities. This is based on the
data obtained from an MSc dissertation of rst author (grant number: 63292) submitted to Tabriz University of Medical Sciences.
Ethics and Approval for human experiments:
This project was found to be in accordance with the ethical principles and the national norms and standards for conducting Medical
Research in Iran. Evaluated by Tabriz University of Medical Sciences. Approval ID: IR.TBZMED.REC.1398.473. In the study, we used
the Rome IV questionnaires for IBS disease (the Rome IV diagnostic questionnaire for IBS disease, Persian versions of IBS-SSS, and
Page 8/15
IBS-QOL questionnaires) after obtaining correspondence and authorization from Rome Foundation. The questionnaires were
provided to the researchers under a contract.
The present trial was approved by the Ethics Committee of Tabriz University of Medical Sciences with ethics code:
IR.TBZMED.REC.1398.473 and was registered in the Iranian registry of clinical trials (, registration date:
26/12/2019, registration number: IRCT20190708044154N1).
1. Rodiño-Janeiro BK, Vicario M, Alonso-Cotoner C, Pascua-García R, Santos J. A review of microbiota and irritable bowel
syndrome: future in therapies. Advances in therapy. 2018;35(3):289-310.
2. Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: A cross
sectional survey. Journal of gastroenterology and hepatology. 2017;32(5):1018-25.
3. Collins S, Piche T, Rampal P. The putative role of inammation in the irritable bowel syndrome. Gut. 2001;49(6):743-5.
4. Ishihara S, Kawashima K, Fukuba N, Tada Y, Kotani S, Mishima Y, et al. Irritable bowel syndrome-like symptoms in ulcerative
colitis patients in clinical remission: association with residual colonic inammation. Digestion. 2019;99(1):46-51.
5. Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World Journal of
Gastroenterology: WJG. 2014;20(22):6759.
6. Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, et al. Ecacy of fecal microbiota transplantation in irritable
bowel syndrome: a systematic review and meta-analysis. American Journal of Gastroenterology. 2019;114(7):1043-50.
7. Zhu Y, Zheng X, Cong Y, Chu H, Fried M, Dai N, et al. Bloating and distention in irritable bowel syndrome: the role of gas
production and visceral sensation after lactose ingestion in a population with lactase deciency. American Journal of
Gastroenterology. 2013;108(9):1516-25.
8. Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The ecacy of probiotics in the treatment of
irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325-32.
9. Suzuki T, Hara H. Role of avonoids in intestinal tight junction regulation. The Journal of nutritional biochemistry.
10. Nina N, Quispe C, Jiménez-Aspee F, Theoduloz C, Feresín GE, Lima B, et al. Antibacterial activity, antioxidant effect and chemical
composition of propolis from the Región del Maule, Central Chile. Molecules. 2015;20(10):18144-67.
11. Cornara L, Biagi M, Xiao J, Burlando B. Therapeutic properties of bioactive compounds from different honeybee products.
Frontiers in pharmacology. 2017;8:412.
12. Xue M, Liu Y, Xu H, Zhou Z, Ma Y, Sun T, et al. Propolis modulates the gut microbiota and improves the intestinal mucosal barrier
function in diabetic rats. Biomedicine & Pharmacotherapy. 2019;118:109393.
13. Wang K, Jin X, Chen Y, Song Z, Jiang X, Hu F, et al. Polyphenol-rich propolis extracts strengthen intestinal barrier function by
activating AMPK and ERK signaling. Nutrients. 2016;8(5):272.
14. Jalali M, Ranjbar T, Mosallanezhad Z, Mahmoodi M, Moosavian SP, Ferns G, et al. Effect of Propolis supplementation on serum
CRP and TNF-α levels in adults: A systematic review and meta-analysis of clinical trials. Complementary Therapies in Medicine.
15. Soleimani D, Miryan M, Tutunchi H, Navashenaq JG, Sadeghi E, GhayourMobarhan M, et al. A systematic review of preclinical
studies on the ecacy of propolis for the treatment of inammatory bowel disease. Phytotherapy Research.
16. Soleimani D, Rezaie M, Rajabzadeh F, Gholizadeh Navashenaq J, Abbaspour M, Miryan M, et al. Protective effects of propolis on
hepatic steatosis and brosis among patients with nonalcoholic fatty liver disease (NAFLD) evaluated by realtime two
dimensional shear wave elastography: A randomized clinical trial. Phytotherapy Research. 2020.
17. Miryan M, Alavinejad P, Abbaspour M, Soleimani D, Ostadrahimi A. Does propolis affect the quality of life and complications in
subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded,
placebo-controlled clinical trial. Trials. 2020;21(1):1-10.
18. Han K, Wang J, Seo J-G, Kim H. Ecacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind
controlled trial. Journal of gastroenterology. 2017;52(4):432-43.
Page 9/15
19. Baştürk A, Artan R, Yılmaz A. Ecacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a
randomized controlled trial. Turk J Gastroenterol. 2016;27(5):439-43.
20. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel
syndrome and its progress. Alimentary pharmacology & therapeutics. 1997;11(2):395-402.
21. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Further validation of the IBS-QOL: a disease-specic
quality-of-life questionnaire. The American journal of gastroenterology. 2000;95(4):999-1007.
22. Fydrich T, Dowdall D, Chambless DL. Reliability and validity of the Beck Anxiety Inventory. Journal of anxiety disorders.
23. Beck AT, Steer R. Beck anxiety inventory (BAI). Überblick über Reliabilitäts-und Validitätsbefunde von klinischen und
außerklinischen Selbst-und Fremdbeurteilungsverfahren. 1988:7.
24. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-
country reliability and validity. Medicine & science in sports & exercise. 2003;35(8):1381-95.
25. A'hern R. Sample size tables for exact singlestage phase II designs. Statistics in medicine. 2001;20(6):859-66.
26. Samadi N, Mozaffari-Khosravi H, Rahmanian M, Askarishahi M. Effects of bee propolis supplementation on glycemic control,
lipid prole and insulin resistance indices in patients with type 2 diabetes: a randomized, double-blind clinical trial. Journal of
Integrative Medicine. 2017;15(2):124-34.
27. Zhao L, Pu L, Wei J, Li J, Wu J, Xin Z, et al. Brazilian green propolis improves antioxidant function in patients with type 2
diabetes mellitus. International journal of environmental research and public health. 2016;13(5):498.
28. Afsharpour F, Javadi M, Hashemipour S, Koushan Y. Propolis supplementation improves glycemic and antioxidant status in
patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Complementary Therapies in Medicine.
29. Mujica V, Orrego R, Pérez J, Romero P, Ovalle P, Zúñiga-Hernández J, et al. The role of propolis in oxidative stress and lipid
metabolism: a randomized controlled trial. Evidence-Based Complementary and Alternative Medicine. 2017;2017.
30. Hesami S, Hashemipour S, Shiri-Shahsavar MR, Koushan Y, Haghighian HK. Administration of Iranian Propolis attenuates
oxidative stress and blood glucose in type II diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial.
Caspian journal of internal medicine. 2019;10(1):48.
31. Pessolato AGT, dos Santos Martins D, Ambrósio CE, Mançanares CAF, de Carvalho AF. Propolis and amnion reepithelialise
second-degree burns in rats. Burns. 2011;37(7):1192-201.
32. Samet N, Laurent C, Susarla SM, Samet-Rubinsteen N. The effect of bee propolis on recurrent aphthous stomatitis: a pilot study.
Clinical oral investigations. 2007;11(2):143-7.
33. Li Y, Xuan H, Shou Q, Zhan Z, Lu X, Hu F-L. Therapeutic effects of propolis essential oil on anxiety of restraint-stressed mice.
Human & experimental toxicology. 2012;31(2):157-65.
34. Soleimani D, Miryan M, Tutunchi H, Navashenaq JG, Sadeghi E, GhayourMobarhan M, et al. A systematic review of preclinical
studies on the ecacy of propolis for the treatment of inammatory bowel disease. Phytotherapy Research. 2020.
35. Al Jaouni SK, Al Muhayawi MS, Hussein A, Elki I, Al-Raddadi R, Al Muhayawi SM, et al. Effects of honey on oral mucositis
among pediatric cancer patients undergoing chemo/radiotherapy treatment at King Abdulaziz University Hospital in Jeddah,
Kingdom of Saudi Arabia. Evidence-Based Complementary and Alternative Medicine. 2017;2017.
36. Orsi R, Funari S, Soares A, Calvi S, Oliveira S, Sforcin J, et al. Immunomodulatory action of propolis on macrophage activation.
Journal of Venomous Animals and Toxins. 2000;6(2):205-19.
37. Tan-no K, Nakajima T, Shoji T, Nakagawasai O, Niijima F, Ishikawa M, et al. Anti-inammatory effect of propolis through
inhibition of nitric oxide production on carrageenin-induced mouse paw edema. Biological and Pharmaceutical Bulletin.
38. Banskota AH, Tezuka Y, Adnyana IK, Midorikawa K, Matsushige K, Message D, et al. Cytotoxic, hepatoprotective and free radical
scavenging effects of propolis from Brazil, Peru, the Netherlands and China. Journal of ethnopharmacology. 2000;72(1-2):239-
39. Alencar S, Oldoni T, Castro M, Cabral I, Costa-Neto C, Cury J, et al. Chemical composition and biological activity of a new type of
Brazilian propolis: red propolis. Journal of ethnopharmacology. 2007;113(2):278-83.
Page 10/15
40. Dobrowolski JW, Vohora S, Sharma K, Shah SA, Naqvi S, Dandiya P. Antibacterial, antifungal, antiamoebic, antiinammatory and
antipyretic studies on propolis bee products. Journal of ethnopharmacology. 1991;35(1):77-82.
41. Massaro FC, Brooks PR, Wallace HM, Russell FD. Cerumen of Australian stingless bees (Tetragonula carbonaria): gas
chromatography-mass spectrometry ngerprints and potential anti-inammatory properties. Naturwissenschaften.
42. Khayyal M, El-Ghazaly M, El-Khatib A. Mechanisms involved in the antiinammatory effect of propolis extract. Drugs under
experimental and clinical research. 1993;19(5):197-203.
43. Song YS, Park E-H, Hur GM, Ryu YS, Kim YM, Jin C. Ethanol extract of propolis inhibits nitric oxide synthase gene expression and
enzyme activity. Journal of Ethnopharmacology. 2002;80(2-3):155-61.
44. Xuan H, Zhu R, Li Y, Hu F. Inhibitory effect of chinese propolis on phosphatidylcholine-specic phospholipase C activity in
vascular endothelial cells. Evidence-Based Complementary and Alternative Medicine. 2010;2011.
45. Mehrnoosh Z, Maryam J, Narjes Z, Hemmati AA, Niloofar N. The Effect of Iranian Propolis on Glucose Metabolism, Lipid Prole,
Insulin Resistance, Renal Function and Inammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized
Double-Blind Clinical Trial. Scientic Reports (Nature Publisher Group). 2019;9(1).
46. Hämäläinen M, Nieminen R, Vuorela P, Heinonen M, Moilanen E. Anti-inammatory effects of avonoids: genistein, kaempferol,
quercetin, and daidzein inhibit STAT-1 and NF-κB activations, whereas avone, isorhamnetin, naringenin, and pelargonidin inhibit
only NF-κB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages.
Mediators of inammation. 2007;2007.
Page 11/15
Table1. Baseline characteristics of the study participants in the both groups.
Variables Propolis group
(N = 26)
Placebo group
(N = 25)
Age; years 38.92 ± 12.65 44.92 ± 12.10 0.090
Females; n (%) 13 (50%) 14 (56%) 0.781
Married; n (%) 19 (73.07%) 23 (92%) 0.076
Academic Education; n (%) 10 (38.46%) 11 (44%) 0.885
Employee; n (%) 20 (77%) 20 (80%) 0.761
METs; minutes/week 691.50 [196.00 - 1629.00] 360.00 [173.25 - 1768.00] 0.883
IBS Duration; years 12.32 ± 10.5 8.31 ± 7.36 0.366
IBS Type IBS-C; n (%) 19 (73.07%) (68%) 17 0.764
IBS-M; n (%)  7 (26.92%) (32%) 8
Anxiety Normal; n (%)  6 (23.1%) 6 (24%) 0.952
Mild; n (%)  8 (30.8%) 6 (24%)
Moderate; n (%) 6 (23.1%) 6 (24%)
Severe; n (%) 6 (23.1%) 7 (28%)
Abbreviations. IBS, Irritable bowel syndrome; IBS-C, Constipation subtype of IBS; IBS-M, Mixed subtype of IBS; METs, Metabolic
Physical activity level are presented as median [25th, 75th]. Age and duration of IBS are presented as mean±SD; other variables
are presented as number (%).
Values were obtained from independent samples t-test.
Values were obtained from Chi-square test.
            
Page 12/15
Table 2. Energy-adjusted nutrients intake across study follow-up
Variables Propolis group Control group Effect
Energy (Kcal) 1200
(389.01) 1263
(391.47) 1287
(454.7) 0.665 1373
(475.28) 1251
(533.31) 1175
(530.36) 0.366 0.851 0.81 0.240
Protein (g) 52.54
(18.44) 54.72
(17.41) 55.19
(17.19) 0.298 60.17
(21.38) 54
(23.47) 51.06
(20.39) 0.801 0.801 0.667 0.251
Fat (g) 22.25
(9.97) 25.34
(5.59) 26.14
(7.04) 0.233 26.60
(10.75) 25.11
(7.54) 24.19
(7.34) 0.580 0.742 0.945 0.164
(g) 119.95
(61.65) 210.04
(63.55) 210.97
(81.53) 0.744 228.49
(77.99) 207.99
(87.78) 191.24
(96.77) 0.305 0.871 0.405 0.238
Soluble Fiber
(g) 270
(130) 290 (10) 320
(110) 0.166 430
(170) 290 (30) 290
(110) 0.178 0.624 0.423 0.134
ber (g) 1560
(1440) 1590
(50) 1770
(690) 0.65 2430
(2050) 1590
(90) 1550
(705) 0.052 0.258 0.149 0.051
(mg) 6090
(1950) 6860
(590) 7520
(1610) 0.223 6870
(2250) 6950
(1045) 7125
(1920) 0.863 0.625 0.980 0.101
Lactose (mg) 3250
(840) 2970
(520) 3920
(1680) 0.004 3680
(1030) 2760
(590) 3510
(1810) 0.023 0.974 0.001 0.172
(mg) 570
(340) 1090
(850) 180 (1) 0.001 870
(520) 1020
(1090) 180 (30) 0.003 0.66 0.001 0.46
Values are expressed as mean (SD).
a Paired sample
b P-intervention for comparing within each group trend, Repeated-measure analysis of variance test.
c P-time, Repeated-measure analysis of variance test.
d P-interaction, Repeated-measure analysis of variance test.
Table 3. Adjusted mean changes in anthropometric parameters in the both groups.
Variables Group Before After P-valueChangesP-value
Weight; kg Propolis 72.10 ± 13.65 72.28 ± 13.84 0.717 0.114 ± 0.094 0.677
Placebo 75.64 ± 15.08 75.61 ± 15.08 0.939 0.063 ± 0.102
BMI; kg/m2Propolis 25.61 ± 4.00 25.58 ± 3.96 0.711 -0.088 ± 0.028 0.775
Placebo 27.75 ± 5.85 27.73 ± 5.81 0.877 0.023 ± 0.031
WC; cm Propolis 85.94 ± 15.77 87.28 ± 2.45 0.711 1.34 ± 0.245 0.593
Placebo 95.20 ± 4.00 94.96 ± 2.74 0.784 -0.23 ± 0.268
Abbreviations. WC: Waist circumference; BMI: Body mass index
Dataare presented as mean ± standard deviation.
Values were obtained from Paired- sample t-test.
Values were obtained from ANCOVA test with baseline values and changes in physical activity and energy intake as covariates.
Page 13/15
Table 4. Quality of life of IBS participants throughout the study.
Variables Propolis (n = 26) Placebo (n = 25) Mean Difference (95 % CI), P
Baseline 59.12 (31.03) 59.61 (28.37) -0.049 (-16.23,17.21), 0.953b
6weeks 72.75 (22.52) 64.54 (25.04) 8.21 (-21.62,5.21), 0.225b, 0.813c,
MD (95 %
 13.6 (-22.11, -5.13),
0.003 1.69 (-14.66, 4.80),
Interference with
activity Baseline 55.85 (25.20) 59.34 (21.40) -3.49 (-9.65, 16,62), 0.597b
6weeks 67.42 (24.55) 54.31 (18.95) 13.11(-25.43, -0.79), 0.037b, 0.424c,
MD (95 %
11.57 (-19.9, -4.05),
0.004 -5.02 (-0.42, 10.48),
Body image
Baseline 70.75 (28.28) 73.63 (13.10) -2.88 (-9.44, 15.21), 0.640b
6weeks 80.89 (19.49) 69.71 (13.62) 11.18 (-20,60, -1.74), 0.021b, 0.039c,
MD (95 %
10.14 (-15.81, -4.46),
0.001 3.91 (-1.24, 9.07),
Health worry Baseline 45.66 (29.96) 47.75 (25.77) -2.09 (-13.61, 17.79), 0.790b
6weeks 63.33 (27.42) 48.39 (23.69) 14.94 (-30.73, -3.14), 0.017b,0.243c,
MD (95 %
17.66 (-30.33, -9.26),
0.001 0.64 (-9.21, 7.68),
Food avoidance Baseline 53.33 (30.80) 53.83 (21.38) -0.5 (-14.89, 15.91), 0.947b
6weeks 64 (22.29) 57.37 (24.41) 6.63 (-21.18, 7.93), 0.365b, 0.876c,
MD (95 %
10.66 (-20.32, -1.01),
0.032 3.52 (-12.95, 5.90),
Social reaction Baseline 70.01 (21.77) 73.55 (21.38) -3.54 (-8.59, 15.69), 0.560b
6weeks 82.26 (14.40) 74.17 (13.54) 8.09 (-15.95, -0.22), 0.044b, 0.415c,
MD (95 %
12.25 (-17.73, -6.76),
0.0001 0.61 (-7.23, 6,00),
Sexual Baseline 72.50 (31.04) 75 (29.36) -2.5 (-14.49, 19,49), 0.769b
6weeks 77 (22.44) 69.23 (31.07) 7.77 (-23.07, 7.53), 0.313b, 0.679c,
MD (95 %
4.5 (-14.13, 5.13), 0.345 5.76 (-6.11, 17.65),
Relationships Baseline 56 (29.41) 58.65 (22.54) -2.65 (-12.05, 17,36), 0.179b
6weeks 66 (23.80) 60.89 (21.57) 5.11 (-17.87, 7.67), 0.426b, 0.803c,
Page 14/15
MD (95 %
10 (-17.75, -2.24), 0.014 2.24 (-9.40, 4.91),
Overall score Baseline 59.90 (24.77) 62.10 (18.31) -2.2 (-10.02, 14.42), 0.719b
6weeks 71.96 (19.24) 62.08 (17.63) 9.88 (-10.13, 14.53), 0.062b, 0.565c,
MD (95 %
12.05 (-18.35, -5.75),
0.001 0.26(-5.87, 5.83),
IBS, Irritable bowel syndrome.
Mean (SD) and Mean Dierence (95 % CI) are presented for data.
a Paired samples
b Independent samples
c ANCOVA test, adjusted for baseline values (Model 1).
d ANCOVA test, adjusted for baseline values, changes in physical activity, and energy intake (Model 2).
Page 15/15
Table 5. IBS symptoms severity score of participants throughout of study.
Variables Propolis (n = 26) Placebo (n = 25) Mean Difference (95 % CI), P
Severity of abdominal
pain Baseline 55.76 ± 28.16 55.60 ± 35.55 0.16 (-17.23, 17.57); 0.984b
6weeks 33.07 ± 26.94 53.60 ± 29.98 - 20.53 (-36.55, -4.49); 0.013b,
0.020c, 0.040d
MD (95%
CI); Pa
-22.69 (-36.18, -9.19);
0.002 -2.00 (-7.38, 11.38);
Frequency of abdominal
pain Baseline 5.15 ± 3.35 5.08 ± 3.39 0.07 (-1.82, 1.97); 0.938b
6weeks 3.07 ± 3.22 4.80 ± 2.76 -1.73 (-3.41, -0.02); 0.046b, 0.150c,
MD (95%
CI); Pa
-2.70 (-3.80, -0.34);
0.021 -0.28 (-1.23, 0.67);
Severity of abdominal
distention Baseline 64.61 ± 32.02 63.60 ± 22.70 1.01(-14.66, 16.69); 0.897b
6weeks 42.69 ± 25.22 48.80 ± 19.64 - 6.11(-18.86, 6.65); 0.341b, 0.327c,
MD (95%
CI), Pa
- 21.92 (-32.82, -11.02);
0.001 -14.80 (-25.79, 3.80);
Dissatisfaction with
bowel habits Baseline 60.00 ± 26.83 64.40 ± 26.93 -4.40 (-19.53, 10.73), 0.562b
6weeks 42.69 ± 23.24 64.00 ± 24.15 -21.31 (-34.64, -7.96), 0.002b,
0.006c, 0.035d
MD (95 %
CI), Pa
-17.30 (-27.56, -7.05),
0.002 -0.40 (-12.34, 13.14),
Interference with quality
of life
Baseline 46.92 ± 35.52 55.60 ± 29.45 -8.68 (-27.07, 9.72), 0.348b
6weeks 34.23 ± 28.16 53.60 ± 24.81 -19.37 (-34.32, -4.40), 0.012b,
0.023c, 0.207d
MD (95 %
CI), Pa
-12.69 (-24,59, -0.78),
0.038 -2.00 (-18.25, 14.25),
Overall score Baseline 288.84 ± 111.40 290.00 ± 108.97 -1.16 (-73.19, 50.88), 0.719b
6weeks 183.46 ± 106.46 268.00 ± 81.54 -84.54 (-138.06, -31.01), 0.003b,
0.008c, 0.036d
MD (95 %
CI), Pa
-95.38 (-139.89,
-50.87), 0.0001 -22.00 (-60.74,
16.74), 0.253
Abbreviation. IBS, Irritable bowel syndrome
Mean (SD) and Mean Dierence (95 % CI) are presented for data.
a Paired samples
b Independent samples
c ANCOVA test, adjusted for baseline values (Model 1).
d ANCOVA test, adjusted for baseline values, changes in physical activity and energy intake (Model 2).
Full-text available
Son yıllarda geleneksel ve tamamlayıcı tıp, apiterapi ve organik ürünlere olan ilgi ve talebin artması ile fonksiyonel bir gıda ürünü olan propolis, alternatif olarak ön plana çıkmış ve bu konuda yapılan araştırmalar artmıştır. Çalışmalarda, propolisin antibakteriyel, antifungal, antiviral, antikanser, antitümör, lokal anestezik, antiinflamatuvar ve antioksidan özellikleri ile kalp ve diyabet gibi kronik hastalıklar, kanser, ağız ve diş hastalıkları, viral hastalıklar, gastrointestinal, nörolojik ve deri hastalıklarında olumlu yönde etkisinin bulunduğu bildirilmiştir. Propolisin standardizasyonu ile ilgili çalışmalar ülkemizde yürütülmekte olup diğer ülkelerde de mevcut çalışmalar içerisinde eksiklikler olmakta ve henüz genel kabul görmüş bir standardizasyon bulunmamaktadır. Bu nedenle, propolisin fonksiyonel özellikleri üzerinde değişen etkiler oluşturması önemli bir sorun olarak karşımıza çıkmaktadır. Ayrıca, doz-yanıt ve yapı-işlev mekanizmasının daha iyi anlaşılmasını sağlayabilecek nitelikte yeni araştırmalara gereksinim duyulmaktadır. Bu derlemede, propolisin bazı hastalıkların tedavisine destek olabilecek ortaya konulmuş faydalı etkilerinin güncel olarak belirlenmesi ve değerlendirilmesi amaçlanmıştır.
Full-text available
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, while no drugs have been approved for its treatment. The pieces of evidence indicate that propolis as a novel anti‐inflammatory agent might be a promising candidate to treat NAFLD. We aimed to evaluate the efficacy of propolis on hepatic steatosis and fibrosis in patients with NAFLD. This randomized clinical trial was conducted on 54 patients with NAFLD. Patients were randomly assigned to receive propolis tablets at a dose of 250 mg twice daily for 4 months or placebo. The improvement in hepatic steatosis and fibrosis was evaluated using two‐dimensional shear wave elastography. Improvement in the hepatic steatosis was significantly higher in the propolis group than the placebo group, even after adjustment for baseline value and changes in weight, energy intake, and physical activity (odds ratio [OR]: 5.67; 95% confidence intervals [CI]: 1.41–22.8; p = .014). A significant reduction was observed on the liver stiffness in the propolis group (−0.65 ± 0.56 kPa; p = .001), whereas it increased in the placebo group (0.27 ± 0.59 kPa; p = .037). Also, the intake of propolis significantly decreased high‐sensitivity C‐reactive protein (hs‐CRP) levels compared with the placebo group (−0.371; 95%CI: −0.582 to −0.16 mg/L; p = .01). Changes in serum levels of fasting blood sugar, alanine aminotransferase, aspartate aminotransferase, low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, cholesterol, and triglyceride did not differ significantly between the two groups (p > .05). There was no significant improvement in insulin resistance in both groups (p > .05). Propolis seems to have protective effects on hepatic steatosis and fibrosis and to reduce the serum levels of hs‐CRP in patients with NAFLD.
Full-text available
Background: Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS. Methods: This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired sample t test or Mann-Whitney U test for the within-group comparison and independent sample t test or Wilcoxon rank-sum and chi-square test or Fisher's exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test. Discussion: We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS. Trial registration: Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020. SPONSOR: Tabriz University of Medical Sciences, Tabriz, Iran.
Full-text available
Objective: Diabetes mellitus is associated with gut microbiota disturbance and intestinal mucosal injuries. This study investigated the influence of propolis on the gut microbiota and intestinal mucosa in rats with diabetes. Methods: Sprague-Dawley (SD) rats were randomly assigned to the control group, model group, and three propolis groups (supplemented with 80, 160, and 240 mg/kg·bw propolis, respectively). A high-fat diet combined with a streptozotocin (STZ) abdominal injection were used to induce diabetes in the rats. After 4 weeks, the intestinal histopathological analysis of the ileum was observed by transmission electron microscopy. The fasting blood glucose (FBG), plasma insulin, glucose tolerance (OGTT) and glycosylated hemoglobin (HbA1c) levels were measured. The expression of tight junction (TJ) proteins in the ileum was measured using western blotting. The molecular ecology of the fecal gut microbiota was analyzed by 16S rDNA high-throughput sequencing. The contents of the short-chain fatty acids (SCFAs) in feces were measured using high-performance liquid chromatography (HPLC). Results: After propolis treatment, compared to the model group, FBG and HbA1c levels declined, while the glucose tolerance and insulin sensitivity index (ISI) increased. The levels of TJ proteins in the ileum increased in the propolis groups. The tight junctions and gap junctions of the intestinal epithelium were also improved in the propolis groups. The contents of the feces acetic acid, propionic acid and butyrate were increased in the propolis groups. 16S rDNA high-throughput sequencing revealed that the composition of the gut microbiota of rats in the propolis supplement group was significantly improved. Conclusions: Compared to the model group, propolis exerted hypoglycemic effects in diabetic rats, and it repaired intestinal mucosal damage, benefited the communities of the gut microbiota and increased SCFA levels in diabetic rats.
Full-text available
Background Hyperglycemia in diabetic people resulted in oxidative conditions. Propolis is the third most important component of bee products which has various functional properties such as anti-oxidant due to its components. The aim of this study was to evaluate the propolis effect on fructosamine level, the catalase activity, and the level of oxidized LDL changes in type 2 diabetic patients. Methods In this double-blind, randomized controlled trial study, 62 type 2 diabetic patients, attending Endocrine clinic in Velayat Hospital (Qazvin, Iran) in 2017, were randomly assigned to one of intervention and placebo (n=31) groups. Participants in intervention group took propolis capsule (500 mg) 3 times a day and those in placebo group took placebo capsules for 8-week. Fructosamine level, catalase activity and the level of oxidized-LDL were measured at the baseline and at the end of the study. Statistical analysis was performed using SPSS software. Results At the end of the study, significant differences were seen within groups and in-between groups. In Propolis group compared to the placebo, fructosamine (p<0.05), and the level of oxidized LDL (p<0.05) decreased, and catalase activity (p<0.05) improved. However, there were no significant changes in the placebo group at the end of trial. Conclusion Eight weeks intake of propolis as a supplement in type II diabetic patients could improve anti-oxidant defense and decline production of hyperglycemia induced products such as fructosamine.
Propolis is a resinous substance produced by bees from plants. There has been some evidence indicating that propolis may be a candidate for the treatment of inflammatory bowel disease (IBD) because of its potent antioxidant properties and ability to modulate immune response and gut microbiome. The objective of this systematic review was to investigate the role of propolis in the treatment of IBD, emphasizing possible mechanisms underlying the anti-inflammatory properties of it. Searches were performed in ISI, PubMed/Medline, Scopus, EMBASE, and Cochrane Library databases up to March 2020. According to the studies examined in this review, the administration of propolis can be useful in attenuating many aspects of clinical, macroscopic, and histological features of colitis in animal models. The efficacy of propolis in the treatment of IBD might be attributed to its potent antioxidants and anti-inflammatory activities. Propolis may also be involved in the modulation of the gut microbiota and in the improvement of the intestinal mucosal barrier function. The major mechanism of action is most likely to be mediated via the prevention of some transcriptional factors and associated proteins. However, future studies are warranted to investigate the clinical utility of propolis as a candidate in the treatment of IBD.
Background Propolis is a natural Product and the antioxidant properties of Propolis appear to be principally responsible for its therapeutic effects. However, several studies have shown the positive effect of Propolis on the reduction the levels of inflammatory markers; some others have revealed non-significant impacts on them. Hence, the present systematic review and meta-analysis was conducted to investigate the effects of Propolis supplementation on inflammatory markers. Methods The systematic search was undertaken in scientific databases that included: PubMed, Embase, Scopus and Web of Science to find studies assessing the effects of Propolis on inflammatory markers up to December 2019. Standardized mean difference (SMD) and 95 % confidence intervals (CI) were pooled using fixed effect model. Potential publication bias was tested using Egger’s regression test. Results Seven studies comprising 471 participants were included in the meta-analysis. Pooled results of this meta-analysis showed that serum TNF-α levels (SMD = -0.52, 95 % CI = [-0.84, -0.20], P = 0.001, I² = 59.5 %) and CRP (SMD = -0.55, 95 % CI = [-0.86, -0.25], P < 0.0001, I² = 41.2 %) were significantly reduced following Propolis supplementation. No evidence of publication bias was found in the meta-analyses. Conclusion The present study concluded in the statistically and clinically improvement of serum CRP and TNF-α levels following Propolis administration.
Objectives: Irritable bowel syndrome (IBS) is a common gastrointestinal condition with a heterogeneous pathophysiology. An altered gut microbiome has been identified in some IBS patients, and fecal microbiota transplantation (FMT) has been suggested to treat IBS. We performed meta-analyses and systematic review of available randomized controlled trials (RCTs) to evaluate the efficacy of FMT in IBS. Methods: We performed a systematic literature search of MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Web of Science. Selection criteria included RCTs of FMT vs placebo using FMT excipients or autologous FMT in IBS. Meta-analyses were conducted to evaluate the summary relative risk (RR) and 95% confidence intervals (CIs) of combined studies for primary outcome of improvement in global IBS symptoms as measured by accepted integrative symptom questionnaires or dichotomous responses to questions of overall symptom improvement. Results: Among 742 citations identified, 7 were deemed to be potentially relevant, of which 4 studies involving 254 participants met eligibility. No significant difference in global improvement of IBS symptoms was observed at 12 weeks in FMT vs placebo (RR = 0.93; 95% CI 0.48-1.79). Heterogeneity among studies was significant (I = 79%). Subgroup analyses revealed benefits of single-dose FMT using colonoscopy and nasojejunal tubes in comparison with autologous FMT for placebo treatment (number needed to treat = 5, RR = 1.59; 95% CI 1.06-2.39; I = 0%) and a reduction in likelihood of improvement of multiple-dose capsule FMT RCTs (number needed to harm = 3, RR = 0.54; 95% CI 0.34-0.85; I = 13%). Placebo response was 33.7% in nonoral FMT RCTs and 67.8% in capsule FMT RCTs. The Grading of Recommendations Assessment, Development and Evaluation quality of the body of evidence was very low. Conclusions: Current evidence from RCTs does not suggest a benefit of FMT for global IBS symptoms. There remain questions regarding the efficacy of FMT in IBS as well as the lack of a clean explanation on the discrepant results among RCTs in subgroup analyses.
Objectives The prevalence of type 2 diabetes has risen dramatically in recent years. There are many different safe therapies used for diabetes and also number of natural supplements that can be used to manage diabetes. We assessed the effect of oral propolis supplementation on blood glucose, insulin resistance and antioxidant status in type 2 diabetes. Methods We conducted a randomized, double-blinded, placebo-controlled trial for 8-week. Sixty two patients with type 2 diabetes (30–55 years of age) were randomly assigned in two group, propolis (n = 31) and placebo (n = 31). Patients were given doses of 500 mg, three times a day (1500 mg), of propolis or placebo three time a day. The fasting blood sugar (FBS), two-hour postprandial glucose (2-hp), insulin, insulin resistance (IR), hemoglobin A1c (HbA1c), total antioxidant capacity (TAC) and activity of glutathione peroxidase (GPx) and superoxide dismutase (SOD) were measured at the beginning and end of the study. Statistical analysis was performed using SPSS software. Results After two month, FBS, 2-hp, insulin, IR, HbA1c was significantly decreased in patients treated with propolis compared with placebo group (p < 0.05). Additionally intake of propolis significantly increased the blood levels of TAC and activity of GPx and SOD (p < 0.05). Conclusion Propolis treatment can be helpful as a diet supplement in patients with type 2 diabetes through improvement in glycemic status, reduction in insulin resistance and amelioration in antioxidant status. This supplement without side effects can increase the effectiveness of prescribing drugs in diabetes.
Ulcerative colitis (UC) patients in clinical remission often experience irritable bowel syndrome (IBS)-like symptoms. The prevalence rate of UC patients meeting the definition of IBS, such as shown by the Rome criteria, is significantly higher in those without ongoing clinical activity as compared to healthy controls. Several studies have investigated residual low-grade inflammation found in colonic mucosa of quiescent UC patients and its association with development of IBS-like symptoms. In these patients, residual colonic inflammation was evaluated using endoscopy and histology findings, as well as fecal calprotectin level and shown to not be simply associated with the presence of IBS-like symptoms in UC patients in clinical remission. However, these results are limited by the low number of related investigations conducted. Additional appropriately designed studies are necessary to confirm the relationship of low-grade colonic inflammation with IBS-like symptoms associated with UC.